At the 48th San Antonio Breast Cancer Symposium 2025 GBG is taking part in the following presentations:
Oral Presentations
Rapid Fire Presentation on December 9, 2025 (17:45 – 17:53 CST):
- Prognostic Impact of TILs & Ki67 in Residual Tumors in TNBC (GeparSixto – GBG 66, GeparSepto – GBG 69, GeparOcto – GBG 84, GeparNuevo – GBG 89, GeparX – GBG 88, and GeparOla – GBG 90)
Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) - a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials
Presenter: J. Holtschmidt
Rapid Fire Presentation on December 9, 2025 (17:53 – 18:01 CST):
- Pooled Analysis of Carboplatin Effect (GeparSixto – GBG 66, BrighTNess, CALGB 40603 (Alliance))
Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer
Presenter: B. Felsheim
Rapid Fire Presentation on December 9, 2025 (18:25 – 18:33 CST):
- GeparDouze Ovarian Substudy (GeparDouze – GBG 96)
Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Substudy of the NSABP B-59/GBG-96-GeparDouze Trial
Presenter: M. Reinisch
Rapid Fire Presentation on December 10, 2025 (13:00 – 13:08 CST)
- DESTINY-Breast05 Interim Analysis (GBG 103)
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05
Presenter: S. Loibl
Educational Session on December 10, 2025 (14:30 – 16:15 CST)
- Moving on up: ADCs in early-stage breast cancer
Presenter: S. Loibl
Rapid Fire Presentation on December 10, 2025 (16:38 – 16:46 CST)
- GeparDouze Study Gene Expression Analysis (GBG 96)
Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial
Presenter: C. Denkert
Oral Presentation on December 11, 2025 (09:15 – 09:30 CST)
- INSEMA Study – Secondary Results on Completion Axillary Dissection (GBG 75)
Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial
Presenter: T. Reimer
Oral Presentation on December 11, 2025 (09:30 – 09:45 CST)
- INSEMA Study – Secondary Results Radiotherapy Analysis (GBG 75)
Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial
Presenter: G. Hildebrandt
Poster Presentations
Poster Presentations on December 11, 2025 (12:30 – 14:00 CST):
- Impact of NACT on Bone Metabolism Measured by Calcium Isotope Ratios – GeparX Study (GBG 88)
Evaluation of stable calcium isotope ratios in women undergoing neoadjuvant chemotherapy (NACT) with and without denosumab (GeparX)
Presenter: M. van Mackelenbergh
Poster Presentation on December 11, 2024 (17:00 - 18:30 CST):
- On-treatment Biopsies: Longitudinal TiLs and Ki67 (GeparSixto – GBG 66, GeparSepto – GBG 69, GeparNuevo – GBG 89, GeparX – GBG 88, and GeparOla – GBG 90)
Predicting response and survival after neoadjuvant systemic treatment with on-treatment biopsies
Presenter: C. Denkert
External contributions with GBG participation
Poster Presentation:
1. AURORA (BIG14-01): Multi-omics characteristics of ER+/HER2- breast cancer switching to metastatic non-luminal subtype: findings from the AURORA study (BIG14-01)
Presenter: M. Benelli
Date: December 10, 2025 (07:00 – 08:30 CST)
2. INAVO120: Comparative analysis of blood- and tissue-based PIK3CA mutation detection methods in the pivotal Phase 3 INAVO120 trial of palbociclib + fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative advanced breast cancer
Presenter: K. Kalinsky
Date: December 10, 2025 (12:30 – 14:00 CST)
4. INAVO120: Molecular features of response to palbociclib + fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial
Presenter: N. C. Turner
Date: December 11, 2025 (07:00 – 08:30 CST)
5. PALLAS: Predictors of early discontinuation of adjuvant palbociclib in early HR+/ HER2- breast cancer: final analysis of the PALLAS trial integrating patient-reported outcomes
Presenter: M. Vetter
Date: December 11, 2025 (12:30 – 14:00 CST)
6. PALLAS: Long-term prognostic and predictive value of lobular histology in the PALLAS trial
Presenter: G. Nader-Marta
Date: December 11, 2025 (12:30 – 14:00 CST)
7. IZABRIGHT-Breast01: Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01)
Presenter: S. Loi
Date: December 12, 2025 (12:30 – 14:00 CST)
Oral Presentations:
1. APHINITY: Prognostic and predictive associations of manual, digital and AI-derived tumor infiltrating lymphocytes-scoring: A retrospective analysis from the Phase III APHINITY trial
Presenter: R. Salgado
Date: December 10, 2025 (09:30 – 12:00 CST)
2. DESTINY-Breast09: Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study
Presenter: M. Rimawi
Date: December 10, 2025 (13:00 – 14:15 CST)
3. Axana/EUBREAST3®: More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy - primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R)study
Presenter: T. Kühn
Date: December 11, 2025 (09:00 – 12:00 CST)
4. CAPItello-291: Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial
Presenter: N. C. Turner
Date: December 11, 2025 (13:00 – 14:00 CST)
5. PATINA: Central nervous system outcomes from the phase III PATINA trial (AFT-38)
Presenter: O. Metzger
Date: December 11, 2025 (16:30 – 17:30 CST)
6. GeparDouze (GBG 96): Evaluation of a whole-exome sequencing tumor-informed circulating tumor DNA MRD assay in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without atezolizumab: A prospective sub study of the NSABP-B59/GBG-96-GeparDouze Trial
Presenter: M. Balic
Date: December 11, 2025 (16:30 – 17:30 CST)
